BioCardia, Inc. 8-K

What Happened

• On April 28, 2026, BioCardia, Inc. announced the allowance of a Japanese patent titled “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation.”
• The company says the patent provides additional protection for its proprietary Heart3D™ Fusion Imaging software, which is used for treatment planning and real‑time navigation during CardiAMP® Cell Therapy procedures.
• A press release describing the allowance was attached to the Form 8‑K as Exhibit 99.1.

Key Details

• Patent title: “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation.”
• Announcement date / 8‑K filed: April 28, 2026.
• Technology covered: Heart3D™ Fusion Imaging software for treatment planning and real‑time navigation in CardiAMP Cell Therapy.
• Disclosure: The 8‑K reported the event under Item 8.01 (Other Events); no financial impact or timing for commercialization was provided in the filing.

Why It Matters

• The allowed Japanese patent broadens BioCardia’s intellectual property protection in an important market, potentially strengthening its competitive position for Heart3D technology in Japan.
• For investors, stronger IP can support commercialization efforts, licensing opportunities, and barriers to direct competition, but the company did not disclose any immediate financial effects or milestones tied to this allowance.
• Monitor future filings or press releases for details on patent issuance, commercialization plans in Japan, regulatory milestones, or any material financial implications.